EVOK - Evoke Pharma, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.7200
+0.1400 (+3.91%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close3.5800
Open3.5900
Bid3.7000 x 1300
Ask3.7200 x 1300
Day's Range3.5500 - 3.7200
52 Week Range0.6900 - 5.0000
Volume880,355
Avg. Volume1,507,906
Market Cap91.894M
Beta (5Y Monthly)2.03
PE Ratio (TTM)N/A
EPS (TTM)-0.2890
Earnings DateMay 12, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Evoke Pharma Set to Gain 170%? This 5-Star Analyst Thinks So
    SmarterAnalyst

    Evoke Pharma Set to Gain 170%? This 5-Star Analyst Thinks So

    Gastrointestinal disease-focused Evoke Pharma (EVOK) kicked off the week in style. Monday, June 22, saw shares go through the roof, and by the end of the trading session, the stock sat on a 62% gain.The surge came after the the company announced it had received the FDA’s nod of approval for its nasal spray, Gimoti, a treatment for diabetic gastroparesis. The condition disrupts the stomach’s contractions, therefore affecting the digestive process. It can lead to nausea and vomiting among other symptoms.H.C. Wainwright analyst Ram Selvaraju believes the approval is well deserved. “We note that it has been a long, hard-fought road to U.S. approval for Gimoti and consider Evoke management’s achievement in securing market authorization for the product particularly laudatory given the challenges that needed to be overcome,” said the analyst.Focus now turns to the commercial opportunity. Evoke has a partnership with EVERSANA Life Sciences, which will oversee the product’s entry to market. The deal dictates Evoke will retain 80% of the profits generated.Selvaraju estimates the company currently has $8 million in cash which should be enough to make it into 2021, regardless of Gimoti sales. The approval also enables the company to access $5 million in funds from EVERSANA under a revolving credit facility. According to Selvaraju, Gimoti’s impact on the balance sheet will come into effect next year.“We are currently projecting only negligible (~$1 million) in Gimoti sales for 2020, which we consider a conservative goal. For 2021, we project $14 million in total sales and roughly $13 million in revenue to Evoke. Assuming this modestly-paced trajectory for Gimoti, we anticipate that Evoke could achieve cash flow breakeven in 1H22,” Selvaraju said.Looking ahead, the analyst expects peak US annual sales to exceed $300 million by 2027. Evoke’s patent for Gimoti is set to expire in 2030.The approval results in a reevaluation from Selvaraju. The 5-star analyst upgraded his rating on the stock from Neutral to Buy. Additionally, Selvaraju set a $10 price target, implying upside potential of approx. 170%. (To watch Selvaraju’s track record, click here)Turning now to the rest of the Street, it has been quiet when it comes to other analyst activity. Selvaraju’s rating is the only recent review of the stock.To find good ideas for biotech stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. More recent articles from Smarter Analyst: * The Rise of E-Commerce and Cloud Services Positions Amazon (AMZN) for the Win * Facebook Faces More Ad Boycotts, But This Analyst Expects Minimal Impact * 3 "Strong Buy" Penny Stocks With Explosive Upside Ahead * Heron Therapeutics: HTX-011 Will Eventually Be Approved, Says Analyst

  • Benzinga

    Price Over Earnings Overview: Evoke Pharma

    In the current session, Evoke Pharma Inc. (NASDAQ: EVOK) is trading at $4.15, after a 76.60% increase. Over the past month, the stock increased by 59.00%, and in the past year, by 639.22%. With performance like this, long-term shareholders optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.Assuming that all other factors are held constant, this could present itself as an opportunity for shareholders trying to capitalize on the higher share price. The stock is currently above from its 52 week high by 48.21%.The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against its past earnings, historical data and aggregate market data for the industry or the indices, such as S&P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also shows that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future.Most often, an industry will prevail in a particular phase of a business cycle, than other industries.Compared to the aggregate P/E ratio of the 0.16 in the Drug Manufacturers--Specialty & Generic industry, Evoke Pharma Inc. has a lower P/E ratio of 0.0. Shareholders might be inclined to think that they might perform worse than its industry peers. It's also possible that the stock is undervalued.price to earnings ratio is not always a great indicator of the company's performance. Depending on the earnings makeup of a company, investors may not be able to attain key insights from trailing earnings.See more from Benzinga * Benzinga's Top Upgrades, Downgrades For June 22, 2020 * 17 Healthcare Stocks Moving In Monday's Pre-Market Session * Stocks That Hit 52-Week Highs On Tuesday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • GlobeNewswire

    FDA Approves Evoke’s GIMOTI™

    Commercial Partner EVERSANA Prepares for GIMOTI LaunchEvoke Extends Cash Runway into 2021 SOLANA BEACH, Calif., June 19, 2020 -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty.

  • GlobeNewswire

    Evoke Receives FDA Conditional Acceptance of Gimoti Brand Name Following NDA Resubmission

    The name Gimoti (pronounced “jye-MOH-tee”) was developed in compliance with FDA’s Guidance for Industry, Contents of a Complete Submission for the Evaluation of Proprietary Names. Based on the development program, which included research with physicians and pharmacists, as well as an international name assessment, the Company believes Gimoti is a proprietary name with strong marketing potential that is also consistent with FDA’s goal of preventing medication errors and potential harm to the public by ensuring that only appropriate proprietary names are approved for use.

  • GlobeNewswire

    Evoke Pharma Reports First Quarter 2020 Financial Results and Changes its 2020 Annual Meeting of Stockholders to a Virtual Format

    Gimoti™ Prescription Drug User Fee Act (PDUFA) date is June 19, 2020 SOLANA BEACH, Calif., May 12, 2020 -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical.

  • GlobeNewswire

    Evoke Pharma Reports Fourth Quarter and Full Year 2019 Financial Results

    SOLANA BEACH, Calif., March 12, 2020 -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today.

  • GlobeNewswire

    Evoke Pharma Receives Notice of Allowance from USPTO for Gimoti™

    Evoke Pharma, Inc. (EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for the Gimoti™ trademark. Gimoti is Evoke’s nasal spray product candidate for the relief of symptoms in adult women with acute and recurrent diabetic gastroparesis. The U.S. Food and Drug Administration (FDA) is currently reviewing the New Drug Application (NDA) for Gimoti and has set a target goal date under the Prescription Drug User Fee Act (PDUFA) of June 19, 2020.

  • GlobeNewswire

    Evoke Pharma Enters Commercialization Agreement with EVERSANA Life Sciences for Gimoti™

    EVERSANA to commercialize and distribute Gimoti in the U.S. SOLANA BEACH, Calif. and CHICAGO, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, and EVERSANA™, an independent provider of global commercial services to the life science industry, today announced a collaboration to utilize EVERSANA’s integrated suite of outsourced services to commercialize and distribute Gimoti™ in the United States (U.S.). Gimoti is Evoke’s nasal spray product candidate for the relief of symptoms in adult women with acute and recurrent diabetic gastroparesis.

  • Evoke Pharma's NDA Resubmission for Gimoti Gets FDA Acceptance
    Zacks

    Evoke Pharma's NDA Resubmission for Gimoti Gets FDA Acceptance

    The FDA receives Evoke Pharma's (EVOK) refiling of new drug application for its pipeline candidate Gimoti, which is being developed to treat diabetic gastroparesis.

  • GlobeNewswire

    FDA Accepts Evoke Pharma’s NDA Resubmission for Gimoti™

    Evoke Pharma, Inc. (EVOK), a specialty pharmaceutical company focused on the development of drugs to treat gastrointestinal (GI) disorders and diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s resubmission of its 505(b)(2) New Drug Application (NDA) for Gimoti™, the Company’s nasal spray product candidate for the relief of symptoms in adult women with acute and recurrent diabetic gastroparesis.

  • GlobeNewswire

    Evoke Resubmits Gimoti™ New Drug Application to FDA

    Evoke Pharma, Inc. (EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has resubmitted its 505(b)(2) New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Gimoti™, the company’s nasal spray product candidate for the relief of symptoms in adult women with acute and recurrent diabetic gastroparesis. The NDA for Gimoti was resubmitted based on feedback received during the Type A meeting with FDA in July 2019.

  • GlobeNewswire

    Evoke Pharma Regains Compliance with Nasdaq Minimum Bid Requirement

    Evoke Pharma, Inc. (EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that on November 29, 2019, it received notification from the Listing Qualifications Department of the Nasdaq Stock Market that the Company has regained compliance with the minimum bid price requirement under Nasdaq’s Marketplace Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. Accordingly, Nasdaq considers the matter closed. Gastroparesis is a debilitating, episodic condition that disproportionately affects adult women and is characterized by slow or delayed gastric emptying of the stomach’s contents after meals, often resulting in flares of symptoms that include nausea, vomiting, abdominal pain and bloating.

  • What Kind Of Shareholder Appears On The Evoke Pharma, Inc.'s (NASDAQ:EVOK) Shareholder Register?
    Simply Wall St.

    What Kind Of Shareholder Appears On The Evoke Pharma, Inc.'s (NASDAQ:EVOK) Shareholder Register?

    A look at the shareholders of Evoke Pharma, Inc. (NASDAQ:EVOK) can tell us which group is most powerful. Institutions...

  • GlobeNewswire

    Evoke Pharma Granted 180-Day Extension by Nasdaq Regarding Minimum Bid Price

    Evoke Pharma, Inc. (EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that on November 12, 2019, it received notification from the Listing Qualifications Department of the Nasdaq Stock Market indicating that the Company has been granted an additional 180-day grace period to regain compliance with the minimum $1.00 bid price per share requirement of Nasdaq’s Marketplace Rule 5550(a)(2). In accordance with the rule, the Company was eligible for the additional compliance period because it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement.

  • GlobeNewswire

    Evoke Pharma Reports Third Quarter 2019 Financial Results

    SOLANA BEACH, Calif., Nov. 07, 2019 -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today.

  • Foamix Initiates Phase II Study on Acne Combination Foam
    Zacks

    Foamix Initiates Phase II Study on Acne Combination Foam

    Foamix (FOMX) enrolls first patient in phase II study on its topical combination foam, FCD105, for the treatment of moderate-to-severe acne vulgaris.

  • When Will Evoke Pharma, Inc. (NASDAQ:EVOK) Come Back To Market?
    Simply Wall St.

    When Will Evoke Pharma, Inc. (NASDAQ:EVOK) Come Back To Market?

    Trailing twelve-month data shows us that Evoke Pharma, Inc.'s (NASDAQ:EVOK) earnings loss has accumulated to -US$7.4m...

  • Zynerba Releases Data on Epilepsy Candidate, Stock Down
    Zacks

    Zynerba Releases Data on Epilepsy Candidate, Stock Down

    Zynerba (ZYNE) announces positive top-line results from the BELIEVE 1 study evaluating the efficacy and safety of Zygel in a heterogeneous group of rare and ultra-rare epilepsies.

  • GlobeNewswire

    Evoke Pharma Completes Manufacturing of Commercial Scale Registration Batches of Gimoti™

    Evoke Pharma, Inc. (EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has completed manufacturing commercial scale batches of its product candidate Gimoti (metoclopramide nasal spray) with its partner Thermo Fisher Scientific, a leading global contract development and manufacturing organization that specializes in the preparation, fill and finish of nasal spray products. Evoke plans to collect Chemistry, Manufacturing and Controls (CMC) data from these registration batches, which were requested in the complete response letter (CRL) from the U.S. Food and Drug Administration (FDA).

  • GlobeNewswire

    Evoke Pharma to Resubmit Gimoti™ NDA Based on FDA Meeting Minutes and Announces Second Quarter 2019 Financial Results

    SOLANA BEACH, Calif., Aug. 08, 2019 -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today.

  • Benzinga

    Biotech Stock On The Radar: Evoke Pharma Sets Date With FDA

    After wallowing in penny stock territory until mid-July, the stock has broken the downtrend seen since early March and is experiencing some upward momentum. The company bought the rights to the investigational asset from Questcor Pharma in 2007 by paying $650,000 upfront and an additional $500,000 in May 2014 as a milestone payment. It is being evaluated as a treatment option for relieving symptoms in adult women with acute and recurrent diabetic gastroparesis.

  • Is Evoke Pharma, Inc. (NASDAQ:EVOK) A Volatile Stock?
    Simply Wall St.

    Is Evoke Pharma, Inc. (NASDAQ:EVOK) A Volatile Stock?

    If you're interested in Evoke Pharma, Inc. (NASDAQ:EVOK), then you might want to consider its beta (a measure of share...